TrialDiabetes care2015

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Simke Demeester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.